Cetrorelix Acetate Injectable Recalled Due to Manufacturing Deviations
Akorn, Inc. recalls all lots of Cetrorelix Acetate for Injection due to manufacturing process deviations. The company went out of business and could not complete required stability testing.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: Class II FDA drug recall with CGMP deviations. No illnesses or injuries reported, and the hazard is theoretical (unverified stability due to inability to complete required studies). Classified as a precautionary recall.
Plain-English summary
Akorn, Inc. is recalling all lots of Cetrorelix Acetate for Injection, 0.25 mg, distributed nationwide in the USA and Puerto Rico. The recall was issued by the FDA due to Current Good Manufacturing Practice (CGMP) deviations.
The company went out of business and could no longer continue the required stability studies for this product. Stability testing is essential to ensure that injected drugs maintain their potency and safety throughout their shelf life. Without completion of these studies, the stability of the product cannot be verified.
Patients who have this medication should consult with their healthcare provider about whether to continue using it. Patients should not stop taking their medication without first talking to their doctor, as this product is used for fertility treatment. Healthcare providers are being notified about this recall.
The recalled product
- Product
- Cetrorelix Acetate for Injection, 0.25 mg, , One carton contains one packaged tray which contains: 1 vial with lyophilized powder for reconstitution, 1 pre-filled syringe with diluent, 1 20-gauge needle, 1 27-gauge needle, Sterile - For subcutaneous use only, Rx Only, Manufacture
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Injectable / Fertility
- Hazard
- cgmp-deviation
- stability-unverified
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27